Inclusion Criteria:

• Age ≥ 18 years.
• Histological confirmation of glioblastoma.
• ECOG Performance Status (PS) ≤ 2 (Appendix I).
• Negative pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only.
• Ability to complete questionnaire(s) by themselves or with assistance.
• Provide written informed consent.
• Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
• Postoperative/post-biopsy tumor plus surgical bed size ≤ 6 cm in maximum diameter.

Exclusion Criteria

• Unable to undergo MRI scans with contrast.
• Unable to undergo an 18F-DOPA-PET scan.
  • Example reasons for inability to complete this scan: Parkinson’s Disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists);
• NOTE: Other potentially interfering drugs: amoxapine, amphetamine, benztropine, buproprion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, paroxetine, citalopram, and sertraline. If a patient is on any of these drugs, list which ones on the On-Study form.
• Any of the following:
  • Men or women of childbearing potential who are unwilling to employ adequate contraception;
  • Nursing women;
  • Pregnant women.
• IDH mutation identified in the tumor on surgical pathology.

Eligibility last updated 7/18/22. Questions regarding updates should be directed to the study team contact.